BioMarin Pharmaceutical NASDAQ: BMRN is betting that a growing rare-disease pipeline and its integration of Amicus will help sustain growth, as executives seek to address investor concerns about competition for its VOXZOGO treatment.
| Quartal / Datum | EPS (USD) | Schätzung (USD) | Abweichung |
|---|
| Quartal / Datum | Umsatz (Mio USD) | Schätzung (Mio USD) | Abweichung |
|---|